"With this successful NDIN, Fuji reaffirms once again its commitment to quality and safety as its number one priority," said Charles DePrince, president of Fuji Health Science. "Also, as earlier testament to this, AstaREAL still remains the only astaxanthin that has successfully petitioned a notification to the FDA for GRAS status also receiving a no-objection letter back in January 2010 for that as well.”
